1003944-35-1

Basic information

• Product Name: 8-bromo-2,7-dimethoxy-1,5-naphthyridine
• CAS NO: 1003944-35-1
• Molecular Weight: 269.098
• Mol File: 1003944-35-1.mol
• Article Data: 3

Chemical Properties

• Boiling Point: 358.5±37.0 °C(Predicted)
• Density: 1.544±0.06 g/cm3(Predicted)
• CAS DataBase Reference: 8-bromo-2,7-dimethoxy-1,5-naphthyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 8-bromo-2,7-dimethoxy-1,5-naphthyridine(1003944-35-1)
• EPA Substance Registry System: 8-bromo-2,7-dimethoxy-1,5-naphthyridine(1003944-35-1)

Safety Data

• Hazardous Substances Data: 1003944-35-1(Hazardous Substances Data)

Usage

General Description

8-Bromo-2,7-dimethoxy-1,5-naphthyridine is a chemical compound with a naphthyridine core structure, featuring bromine and methoxy functional groups. It is often used in pharmaceutical research and drug development, with potential applications in the treatment of various medical conditions. The bromine atom and methoxy groups contribute to the compound's chemical properties, affecting its solubility, reactivity, and biological activity. Research on 8-bromo-2,7-dimethoxy-1,5-naphthyridine continues to explore its potential as a drug candidate or as a chemical tool for further investigations into its biological effects and mechanisms of action.

Upstream product

• 724788-70-9 8-bromo-7-fluoro-2-methoxy-1,5-naphthyridine 
• 124-41-4 sodium methylate 

Downstream Products

• 1173896-46-2 1-(2-(4-((3,4-dichlorobenzyl)amino)piperidin-1-yl)ethyl)-7-methoxy-1,5-naphthyridin-2(1H)-one 
• 959615-59-9 7-methoxy-1,5-naphthyridin-2(1H)-one 

Relevant articles and documents

Mycobacterium tuberculosis gyrase inhibitors as a new class of antitubercular drugs

One way to speed up the TB drug discovery process is to search for antitubercular activity among compound series that already possess some of the key properties needed in anti-infective drug discovery, such as whole-cell activity and oral absorption. Here, we present MGIs, a new series of Mycobacterium tuberculosis gyrase inhibitors, which stem from the long-term efforts GSK has dedicated to the discovery and development of novel bacterial topoisomerase inhibitors (NBTIs). The compounds identified were found to be devoid of fluoroquinolone (FQ) cross-resistance and seem to operate through a mechanism similar to that of the previously described NBTI GSK antibacterial drug candidate. The remarkable in vitro and in vivo antitubercular profiles showed by the hits has prompted us to further advance the MGI project to full lead optimization.

Compounds

Compounds of Formula (I), compositions containing them, their use in therapy, including their use as antibacterials, for example in the treatment of tuberculosis, and methods for the preparation of such compounds, are provided.